Akynzeo (Netupitant and Palonosetron)
Brand Names: Akynzeo
Methodology & AI Transparency ⓘ
Akynzeo (Netupitant and Palonosetron) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: FDA DailyMed monograph 2026-06-23 designates Akynzeo (NDC 69639-101, 69639-102, registered by Helsinn Therapeutics (U.S.), Inc.) as a prescription brand-name substance p/neurokinin-1 receptor antagonist formulation of Netupitant and Palonosetron.
- 2 Real-world patient consensus: Commercial Akynzeo monograph (300 mg/1 / .5 mg/1 Capsule) cross-indexed with generic Netupitant and Palonosetron for therapeutic equivalence review.
- 3 Typical cash cost range: Dispensing cost comparison spans $256.90 mail/discount cash up to $680.78 uninsured retail (federal NADAC $3.4500).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Akynzeo (Netupitant and Palonosetron) include nausea (11.3%), headache (9.9%), fatigue (9%).
Ask our AI Specialists anything about Akynzeo (Netupitant and Palonosetron)
Akynzeo (Netupitant and Palonosetron) Mechanism, CYP450 Pathways & DailyMed Monograph
FDA DailyMed monograph 2026-06-23 designates Akynzeo (NDC 69639-101, 69639-102, registered by Helsinn Therapeutics (U.S.), Inc.) as a prescription brand-name substance p/neurokinin-1 receptor antagonist formulation of Netupitant and Palonosetron. Supplied across 300 mg/1 / .5 mg/1 Capsule; 260 mg/20mL / .28 mg/20mL Injection, Akynzeo is utilized in 1 Indications and usage akynzeo: capsules is indicated in combination with dexamethasone in adults for the prevention of.
Clinical pharmacology for Akynzeo is driven by Netupitant and Palonosetron acting within substance p/neurokinin-1 receptor antagonist signaling cascades involving CYP3A4 clearance pathways. Distributed across 300 mg/1 / .5 mg/1 Capsule; 260 mg/20mL / .28 mg/20mL Injection (NDC 69639-101, 69639-102; registered by Helsinn Therapeutics (U.S.), Inc.), the branded formulation calibrates systemic exposure and patient adherence, with public 30-day cash benchmarks ranging from $256.90 to $680.78.
With Elimination kinetics span 8 to 21 hours per Akynzeo (Netupitant and Palonosetron) clinical pharmacology residence kinetics and Consistent 67%–79% gastrointestinal absorption profile for Akynzeo (Netupitant and Palonosetron) bioavailability, Akynzeo (Netupitant and Palonosetron) undergoes cytochrome cyp3a4 biotransformation with dual hepatorenal elimination and establishes therapeutic activity over cmax attained 2–5 hours post-administration of akynzeo (netupitant and palonosetron).
Standard adult regimens span 300 mg/1 / .5 mg/1 Capsule, 260 mg/20mL / .28 mg/20mL Injection. Prescribers screen specifically against history of severe allergic sensitivity to akynzeo (netupitant and palonosetron) active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2026-06-23 netupitant and palonosetron labeling, while community micro-logs most frequently note nausea (11.3% of reports), headache (9.9% of reports), fatigue (9% of reports).
Systemic bioavailability and half-life of Akynzeo (Netupitant and Palonosetron) respond to strong CYP3A4 enzymatic inhibition or induction.
Verify medication reconciliation lists so Akynzeo (Netupitant and Palonosetron) is not inadvertently duplicated with another substance p/neurokinin-1 receptor antagonist.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Akynzeo (Netupitant and Palonosetron) active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2026-06-23 Netupitant and Palonosetron labeling
Logged Side-Effect Incidence (19 Reports)
Akynzeo (Netupitant and Palonosetron) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Akynzeo (Netupitant and Palonosetron))
Human clinical trial evidence for Akynzeo (Netupitant and Palonosetron) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Akynzeo (Netupitant and Palonosetron) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.4500/unit (~$103.50/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $680.78 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 19 Anonymous DotMD Community Micro-Logs | $256.90 / mo | View logs ↓ |
Akynzeo (Netupitant and Palonosetron) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Akynzeo (Netupitant and Palonosetron) RxNorm Concept ID | 1552349 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.4500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $680.78 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $256.90 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 82.00% Worth It (19 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Akynzeo (Netupitant and Palonosetron) Patient Community, Cohort Filters & Dosage Logs
Deterministic Akynzeo (Netupitant and Palonosetron) reference combining NIH RxNorm (1552349), Medicaid NADAC ($3.4500/unit), and anonymous cohort outcomes (82% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Akynzeo (Netupitant and Palonosetron) community threads and patient logs by age, biological sex, dosage, and treatment duration.